Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glaxo: Getting leaner - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 30, 2003

    Glaxo: Getting leaner

    MNC Pharma major, GlaxoSmithKline (GSK), has improved its topline during the June quarter. After registering a 2.5% topline dip in the March quarter, the company has reported over 10% growth in the same during the June quarter. The company had attributed the topline dip in the March quarter to VAT concerns. Going by the June quarter performance it seems that the domestic pharma industry is back on track.

    (Rs m) 2QFY03 2QFY04 Change 1HFY03 1HFY04 Change
    Net Sales 2,734 3,015 10.3% 5,390 5,603 4.0%
    Other Income 96 135 41.4% 165 230 39.3%
    Total expenditure 2,145 2,268 5.7% 4,421 4,357 -1.4%
    Operating Profit (EBDIT) 589 747 26.7% 969 1,246 28.6%
    Operating Profit Margin (%) 21.5% 24.8%   18.0% 22.2%  
    Depreciation 47 44 -5.4% 94 88 -6.9%
    Profit before Tax 638 838 31.3% 1,040 1,389 33.5%
    Extraordinary items -2 123 - -32 123 -
    Tax 231 313 35.8% 372 513 37.9%
    Profit after Tax/(Loss) 406 648 59.7% 636 999 57.1%
    Effective tax rate (%) 36.1% 37.4%   35.8% 36.9%  
    Net profit margin (%) 14.8% 21.5%   11.8% 17.8%  
    No. of Shares (eoy) (m) 74.5 74.5   74.5 74.5  
    Earnings per share* 21.8 34.8   17.1 26.8  
    Current P/e ratio   11.7     15.2  

    Its core business of pharmaceuticals (over 80% of sales) reported 5.7% growth during first half of 2003, much above the industry growth rate of 2.5% during the period. Export sales during the half year declined by 47% mainly due to the discontinuation of Ranitidine exports post the Ankleshwar site closure. This had an impact on the company’s overall sales performance during the half year. Its other businesses recorded a drop of 12% in sales during six months. Consequently, GSK finished 1HFY04 with only a 4% topline growth (excluding excise).

    Improving efficiencies continued to help GSK post higher operating margins. Though in the June quarter, material cost as a percentage of sales did see an uptick, for the overall first half of the year material cost as a percentage of sales stayed below 48% (49.3% in 1HFY03). The company's focus on power brands that are more profit making (i.e. not under DPCO) seems to be yielding results. In FY03, the company's operating margins had improved by over 6% at 16.6%. Continuing the trend, operating margins have improved from 18% to over 22% in the first half of FY04. Consequently, GSK finished 1HFY04 with a 34% growth at the PBT levels.

    Segment revenue break-up
    (Rs m) 2QFY03 2QFY04 Change 1HFY03 1HFY04 Change
    Pharmaceuticals 2,553 2,759 8.1% 4,882 5,162 5.7%
    Others businesses 594 564 -5.0% 1,177 1,036 -12.0%
    Total segment revenue 3,147 3,323 5.6% 6,058 6,198 2.3%

    Post the merger with SmithKline, GSK has increasingly looked to close down unviable plants and also looked to increase outsourced manufacturing. It is looking at selling off property (of erstwhile SmithKline) and streamlining operations of both companies for optimal utilisation (through VRS). Consequently, the company's depreciation provisioning too has come down. The spurt in other income suggests that it is reaping the benefits of investible funds. GSK Consumer's estimated surplus cash stands at nearly Rs 2 bn.

    Segment (PBIT) break-up
    (Rs m) 2QFY03 2QFY04 Change 1HFY03 1HFY04 Change
    Pharmaceuticals 611 746 22.2% 961 1,218 26.8%
    Others businesses 82 89 9.7% 167 158 -5.2%
    Gross PBIT 692 836 20.7% 1,127 1,376 22.1%
    Add: Interest income (net) 11 49 362.9% 24 91 273.3%
    Less: Unallocable exp. (net) -65 -46 - -112 -78 -
    Total PBIT 638 838 31.3% 1,040 1,389 33.5%

    The extraordinary items mentioned in 1HFY04 represents Rs 123 m received as profit on sale of its Bangalore office property. The company is also in the process of selling its Mumbai property, which is estimated to fetch the company nearly Rs 1 bn over the next few quarters.

    At the current price of Rs 385, the stock is trading at a P/E multiple of 14.4x its annualised 1HFY04 earnings. The company is gearing itself towards 2005, when the patent regime comes into force. The company is also likely to finalise the much awaited merger with Burroughs Wellcome soon.



    Equitymaster requests your view! Post a comment on "Glaxo: Getting leaner". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)


    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Quarterly Results With Charts